-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CSL-787 in Bronchiectasis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CSL-787 in Bronchiectasis Drug Details: CSL-787 is under development for the treatment of non-cystic fibrosis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CSL-346 in Diabetic Nephropathy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CSL-346 in Diabetic Nephropathy Drug Details:CSL-346 (VEGF-B antagonist) is under development for the treatment of diabetic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CSL-346 in Lipid Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CSL-346 in Lipid Disorders Drug Details:CSL-346 (VEGF-B antagonist) is under development for the treatment of diabetic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Garadacimab in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Drug Details: Garadacimab (CSL-312) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Idiopathic Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Garadacimab in Idiopathic Pulmonary Fibrosis Drug Details: Garadacimab (CSL-312) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Garadacimab in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drug Details:Garadacimab (CSL-312) is under development...
-
Product Insights
![]()
CSL Behring – Broadmeadows Manufacturing Plant Expansion – Victoria
Equip yourself with the essential tools needed to make informed and profitable decisions with our CSL Behring - Broadmeadows Manufacturing Plant Expansion - Victoria report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
![]()
CSL Behring – Kankakee Manufacturing Plant Expansion – Illinois
Equip yourself with the essential tools needed to make informed and profitable decisions with our CSL Behring - Kankakee Manufacturing Plant Expansion - Illinois report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Age Related Macular Degeneration
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Age Related Macular Degeneration Drug Details: Iptacopan (LNP-023) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ARX-517 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ARX-517 in Pancreatic Cancer Drug Details:ARX-517 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anumigilimab in Rheumatoid Arthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anumigilimab in Rheumatoid Arthritis Drug Details: Anumigilimab (CSL324) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anumigilimab in Chronic Obstructive Pulmonary Disease (COPD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anumigilimab in Chronic Obstructive Pulmonary Disease (COPD) Drug Details: Anumigilimab (CSL324) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anumigilimab in Palmoplantar Pustulosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anumigilimab in Palmoplantar Pustulosis Drug Details: Anumigilimab (CSL324) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anumigilimab in Hidradenitis Suppurativa
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anumigilimab in Hidradenitis Suppurativa Drug Details: Anumigilimab (CSL324) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Livmoniplimab in Solid Tumor Drug Details: Livmoniplimab (ABBV-151) is under development for the treatment of...
-
Sector Analysis
New![]()
Heart Failure in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Heart Failure Market Report Overview The heart failure market size across the 7MM was valued at $31.9 billion in 2022 and is expected to achieve a CAGR of more than 5% during 2022-2032. The 7MM includes the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. GlobalData expects uptake of SGLT2 inhibitors and three first-in-class drugs to be the strongest driver of the total heart failure markets in the 7MM. Heart Failure Market Outlook, 2022-2032 ($ Billion) Buy...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STI-6643 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STI-6643 in Solid Tumor Drug Details: STI-6643 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HU-6 in Diastolic Heart Failure
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HU-6 in Diastolic Heart FailureDrug Details:HU-6 is under development for the treatment of non-alcoholic steatohepatitis (NASH),...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cudetaxestat in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Cudetaxestat in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Drug Details: Cudetaxestat is under...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.